|
1) Necessity of COVID-19 vaccination in previously infected individuals, Shrestha, 2021
|
|
2) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Le Bert, 2020
|
|
3) Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Gazit, 2021
|
|
4) Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection, Le Bert, 2021
|
|
5) Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection, Israel, 2021
|
|
6) SARS-CoV-2 re-infection risk in Austria, Pilz, 2021
|
|
7) mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on prior infection status, Neidleman, 2021
|
|
8) Good news: Mild COVID-19 induces lasting antibody protection, Bhandari, 2021
|
|
9) Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Wajnberg, 2021
|
|
10) Evolution of Antibody Immunity to SARS-CoV-2, Gaebler, 2020
|
|
11) Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans, Haveri, 2021
|
|
12) Quantifying the risk of SARS‐CoV‐2 reinfection over time, Murchu, 2021
|
|
13) Natural immunity to covid is powerful. Policymakers seem afraid to say so, Makary, 2021
The Western Journal-Makary
|
|
14) SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity, Nielsen, 2021
|
|
15) Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, Goldberg, 2021
|
|
16) Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, Kojima, 2021
|
|
17) Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital, Wadman, 2021
|
|
18) One-year sustained cellular and humoral immunities of COVID-19 convalescents, Zhang, 2021
|
|
19) Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19, Rodda, 2021
|
|
20) Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection, Ivanova, 2021
|
|
21) SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans, Turner, 2021
|
|
22) SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN), Jane Hall, 2021
|
|
23) Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers, Houlihan, 2020
|
|
24) Antibodies to SARS-CoV-2 are associated with protection against reinfection, Lumley, 2021
|
|
25) Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, Cohen, 2021
|
|
26) Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine, Sureshchandra, 2021
|
|
27) SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, Abu-Raddad, 2021
|
|
28) Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity, Ripperger, 2020
|
|
29) Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, Wei, 2021
|
|
30) Researchers find long-lived immunity to 1918 pandemic virus, CIDRAP, 2008
and the actual 2008 NATURE journal publication by Yu
|
|
31) Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, Gonzalez, 2021
|
|
32) Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, Camara, 2021
|
|
33) Op-Ed: Quit Ignoring Natural COVID Immunity, Klausner, 2021
|
|
34) Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection, Harvey, 2021
|
|
35) SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study, Letizia, 2021
|
|
36) Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar, Bertollini, 2021
|
|
37) Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, Mishra, 2021
|
|
38) Lasting immunity found after recovery from COVID-19, NIH, 2021
|
|
39) SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, Petersen, 2021
|
|
40) SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jung, 2021
|
|
41) Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, Ansari, 2021
|
|
42) COVID-19 natural immunity, WHO, 2021
|
|
43) Antibody Evolution after SARS-CoV-2 mRNA Vaccination, Cho, 2021
|
|
44) Humoral Immune Response to SARS-CoV-2 in Iceland, Gudbjartsson, 2020
|
|
45) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Dan, 2021
|
|
46) The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis of 12 011 447 individuals, Chivese, 2021
|
|
47) Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study, Sheehan, 2021
|
|
48) Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy, Vitale, 2020
|
|
49) Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection, Hanrath, 2021
|
|
50) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Grifoni, 2020
|
|
51) NIH Director’s Blog: Immune T Cells May Offer Lasting Protection Against COVID-19, Collins, 2021
|
|
52) Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants, Wang, 2021
|
|
53) Why COVID-19 Vaccines Should Not Be Required for All Americans, Makary, 2021
|
|
54) Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence, Ma, 2021
|
|
55) Decrease in Measles Virus-Specific CD4 T Cell Memory in Vaccinated Subjects, Naniche, 2004
|
|
56) Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination, Palm, 2019
|
|
57) SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern, Lyski, 2021
|
|
58) Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection, Wang, 2021
|
|
59) CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants, Redd, 2021and Lee, 2021
|
|
60) Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2,La Jolla, Crotty and Sette, 2020
|
|
61) Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans, Mateus, 2020
|
|
62) Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection, Dehgani-Mobaraki, 2021
|
|
63) Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19, Juno, 2020
|
|
64) Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Robbiani, 2020
|
|
65) Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence, Hartley, 2020
|
|
66) Had COVID? You’ll probably make antibodies for a lifetime, Callaway, 2021
|
|
67) A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2, Majdoubi, 2021
|
|
68) SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19, Braun, 2020
Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors, Braun, 2020
|
|
69) Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection, Wang, 2021
|
|
70) One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms, Rank, 2021
|
|
71) IDSA, 2021
|
|
72) Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study, Holm Hansen, 2021
|
|
73) Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity, Moderbacher, 2020
|
|
74) Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals, Ni, 2020
|
|
75) Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection, Zuo, 2020
|
|
76) Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees, Tarke, 2021
|
|
77) A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report, Perez, 2021
|
|
78) Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, Iyer, 2020
|
|
79) A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States, Alfego, 2021
|
|
80) What are the roles of antibodies versus a durable, high- quality T-cell response in protective immunity against SARS-CoV-2? Hellerstein, 2020
|
|
81) Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients, Peng, 2020
|
|
82) Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19, Sekine, 2020
|
|
83) Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients, Lafron, 2021
|
|
84) SARS-CoV-2 T-cell epitopes define heterologous and COVID-19 induced T-cell recognition, Nelde, 2020
|
|
85) Karl Friston: up to 80% not even susceptible to Covid-19, Sayers, 2020
|
|
86) CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses, Lineburg, 2021
|
|
87) SARS-CoV-2 genome-wide mapping of CD8 T cell recognition reveals strong immunodominance and substantial CD8 T cell activation in COVID-19 patients, Saini, 2020
|
|
88) Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis, Shenai, 2021
|
|
89) ChAdOx1nCoV-19 effectiveness during an unprecedented surge in SARS CoV-2 infections, Satwik, 2021
|
|
90) SARS-CoV-2 specific T cells and antibodies in COVID-19 protection: a prospective study, Molodtsov, 2021
|
|
91) Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination, Cho, 2021
|
|
92) Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses, Ortega, 2021
|
|
93) Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals, Mahajan, 2021
|
|
94) Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients, Wang, 2020
|
|
95) Not just antibodies: B cells and T cells mediate immunity to COVID-19, Cox, 2020
|
|
96) T cell immunity to SARS-CoV-2 following natural infection and vaccination, DiPiazza, 2020
|
|
97) Durable SARS-CoV-2 B cell immunity after mild or severe disease, Ogega, 2021
|
|
98) Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection., Ng, 2016
|
|
99) Adaptive immunity to SARS-CoV-2 and COVID-19, Sette, 2021
|
|
100) Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients, Tan, 2021
|
|
101) SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals, Kared, 2021
|
|
102) S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit, Nguyen-Contant, 2021
|
|
103) Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection, Yao, 2021
|
|
104) Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection, De Giorgi, 2021
|
|
105) Decreasing Seroprevalence of Measles Antibodies after Vaccination – Possible Gap in Measles Protection in Adults in the Czech Republic, Smetana, 2017
|
|
106) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection, Wrammert, 2011
|
|
107) Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing, Qureshi, 2021
|
|
108) Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination, Goel, 2021
|
|
109) Covid-19: Do many people have pre-existing immunity? Doshi, 2020
|
|
110) Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans, Ng, 2020
|
|
111) Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome, Weiskopf, 2020
|
|
112) Pre-existing immunity to SARS-CoV-2: the knowns and unknowns, Sette, 2020
|
|
113) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population, Greenbaum, 2009
|
|
114) Cellular immune correlates of protection against symptomatic pandemic influenza, Sridhar, 2013
|
|
115) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans, Wilkinson, 2012
|
|
116) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine, CDC, MMWR, 2009
|
|
117) No one is naive: the significance of heterologous T-cell immunity, Welsh, 2002
|
|
118) Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion, Gallais, 2020
|
|
119) Protective immunity after recovery from SARS-CoV-2 infection, Kojima, 2021
|
|
120) This ‘super antibody’ for COVID fights off multiple coronaviruses, Kwon, 2021
|
|
121) SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19, Wu, 2020
|
|
122) Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients, Isho, 2020
|
|
123) The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role, Bertoletti, 2021
|
|
124) The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months, Eyran, 2020
|
|
125) Continued Effectiveness of COVID-19 Vaccination among Urban Healthcare Workers during Delta Variant Predominance, Lan, 2021
|
|
126) Immunity to COVID-19 in India through vaccination and natural infection, Sarraf, 2021
|
|
127) Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents, Garrido, 2021
|
|
128) T cell response to SARS-CoV-2 infection in humans: A systematic review, Shrotri, 2021
|
|
129) Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections, Abu-Raddad, 2021
|
|
130) Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Re-exposure Setting, Abu-Raddad, 2021
|